{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:41:29Z","timestamp":1789400489611,"version":"build-2803163510"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Human umbilical cord mesenchymal stem cells (UCMSCs) are being investigated in various clinical trials for different conditions, including type 2 diabetes mellitus (T2DM). However, there is limited research on the optimal injection routes for UCMSCs in T2DM, particularly intravenous injection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study aims to investigate the efficacy of four different administration routes of UCMSCs in treating T2DM rats, including pancreas injection (DP), tail vein injection (DT), intraperitoneal injection (DI), and dorsal pancreatic artery injection (DPA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After two weeks of UCMSCs treatment, the fasting blood glucose levels in the DT group decreased significantly. The oral glucose tolerance test (OGTT) levels and the islet structure in the DT group almost recovered to normal. The contents of C-P and GLP-1 in serum increased significantly in all treatment groups, while the levels of INS, TNF-\u03b1, IL-6, IL-1\u03b2, IAA, and GSP decreased significantly. These improvements were further observed after four weeks of UCMSCs treatment. Histological analysis confirmed the progression of pancreatic recovery in all treatment groups, with the DT group showing the most significant improvement, correlating with the observed efficacy. Immunohistochemistry results further demonstrated increased insulin and PDX-1 expression, along with reduced glucagon levels in UCMSCs-treated rats. Additionally, liver and kidney function significantly improved across all treatment groups, with the DT group showing the best outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, these findings suggest that the administration route significantly affected the efficacy of UCMSCs in treating T2DM, with tail vein injection showing the most effective results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1536655","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T01:18:18Z","timestamp":1742519898000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of administration routes on the efficacy of human umbilical cord mesenchymal stem cells in type 2 diabetic rats"],"prefix":"10.3389","volume":"16","author":[{"given":"Qiqiang","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youzhi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiwen","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinglei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenrui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuqiang","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicity Y.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"15019","DOI":"10.1038\/nrdp.2015.19","article-title":"Type 2 diabetes mellitus","volume":"1","author":"Defronzo","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"103393","DOI":"10.1016\/j.drudis.2022.103393","article-title":"Progress in oral insulin delivery by PLGA nanoparticles for the management of diabetes","volume":"28","author":"Pang","year":"2023","journal-title":"Drug Discovery Today"},{"key":"B3","doi-asserted-by":"publisher","first-page":"555568","DOI":"10.19080\/CRDOJ.2017.1.555568","article-title":"Can diabetes be controlled by lifestyle activities","volume":"1","author":"Reddy","year":"2017","journal-title":"Curr Res Diabetes Obes J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/dme.v37.10","article-title":"Burden of disease of type 2 diabetes mellitus: cost of illness and quality of life estimated using the Maastricht Study","volume":"37","author":"Janssen","year":"2020","journal-title":"Diabetes Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"155223","DOI":"10.1016\/j.metabol.2022.155223","article-title":"Metformin: Is it a drug for all reasons and diseases","volume":"133","author":"Triggle","year":"2022","journal-title":"Metabolism"},{"key":"B6","doi-asserted-by":"publisher","first-page":"6275","DOI":"10.3390\/ijms21176275","article-title":"Pathophysiology of type 2 diabetes mellitus","volume":"21","author":"Galicia-Garcia","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1051528","article-title":"Human umbilical cord mesenchymal stem cells: an overview of their potential in cell-based therapy","volume":"15","author":"Li","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01134-4","article-title":"Stem cell-based therapy for human diseases","volume":"7","author":"Hoang","year":"2022","journal-title":"Signal Transduction Targeted Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3727\/096368915X686841","article-title":"Human umbilical cord mesenchymal stem cells: A new era for stem cell therapy","volume":"24","author":"Ding","year":"2015","journal-title":"Cell Transplant"},{"key":"B10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.21315\/mjms2023.30.2.5","article-title":"Human mesenchymal stromal cells derived from perinatal tissues: sources, characteristics and isolation methods","volume":"30","author":"Teoh","year":"2023","journal-title":"Malays J Med Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13287-021-02222-y","article-title":"Human umbilical cord-derived mesenchymal stem\/stromal cells: a promising candidate for the development of advanced therapy medicinal products","volume":"12","author":"Mebarki","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.reth.2022.07.005","article-title":"Human umbilical cord mesenchymal stem cell-derived exosomes promote neurological function recovery in rat after traumatic brain injury by inhibiting the activation of microglia and astrocyte","volume":"21","author":"Cui","year":"2022","journal-title":"Regener Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13287-021-02158-3","article-title":"The therapeutic applications of mesenchymal stromal cells from human perinatal tissues in autoimmune diseases","volume":"12","author":"Yang","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.87472","article-title":"Human umbilical cord mesenchymal stem cells in diabetes mellitus and its complications: applications and research advances","volume":"20","author":"Li","year":"2023","journal-title":"Int J Med Sci"},{"key":"B15","article-title":"Transplantation of umbilical cord mesenchymal stem cells via different routes in rats with acute liver failure","volume":"8","author":"Zheng","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2016.0275","article-title":"Efficacy of autologous bone marrow-Derived mesenchymal stem cell and mononuclear cell transplantation in type 2 diabetes mellitus: A randomized, placebo-Controlled comparative study","volume":"26","author":"Bhansali","year":"2017","journal-title":"Stem Cells Dev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.15283\/ijsc18076","article-title":"The effect of liraglutide in combination with human umbilical cord mesenchymal stem cells treatment on glucose metabolism and \u03b2 cell function in type 2 diabetes mellitus","volume":"12","author":"Hwang","year":"2019","journal-title":"Int J Stem Cells"},{"key":"B18","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s13287-021-02417-3","article-title":"One repeated transplantation of allogeneic umbilical cord mesenchymal stromal cells in type 1 diabetes: an open parallel controlled clinical study","volume":"12","author":"Lu","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/stcltm\/szad060","article-title":"Efficacy of umbilical cord-derived mesenchymal stem cells in the treatment of type 2 diabetes assessed by retrospective continuous glucose monitoring","volume":"12","author":"Zang","year":"2023","journal-title":"Stem Cells Transl Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2017.08.098","article-title":"A practical guide for induction of type-2 diabetes in rat: Incorporating a high-fat diet and streptozotocin","volume":"95","author":"Gheibi","year":"2017","journal-title":"BioMed Pharmacother"},{"key":"B21","doi-asserted-by":"publisher","first-page":"7921","DOI":"10.1038\/s41598-023-29445-8","article-title":"Comparative impact of streptozotocin on altering normal glucose homeostasis in diabetic rats compared to normoglycemic rats","volume":"13","author":"Rehman","year":"2023","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/dom.v24.11","article-title":"The glucose tolerance test in mice: Sex, drugs and protocol","volume":"24","author":"Kennard","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e7079","DOI":"10.7717\/peerj.7079","article-title":"The role of serum and urinary biomarkers in the diagnosis of early diabetic nephropathy in patients with type 2 diabetes","volume":"7","author":"Zhang","year":"2019","journal-title":"PeerJ"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-023-01504-7","article-title":"Development of polysaccharide-coated layered double hydroxide nanocomposites for enhanced oral insulin delivery","volume":"14","author":"Pang","year":"2024","journal-title":"Drug Delivery Transl Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41421-024-00762-0","article-title":"A tumor-secreted protein utilizes glucagon release to cause host wasting","volume":"11","author":"Ding","year":"2025","journal-title":"Cell Discovery"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2016.08.08","article-title":"Immunohistochemistry for pathologists: protocols, pitfalls, and tips","volume":"50","author":"Kim","year":"2016","journal-title":"J Pathol Trans Med"},{"key":"B27","article-title":"Estimating the size of treatment effects: moving beyond p values","volume":"6","author":"McGough","year":"2009","journal-title":"Psychiatry (Edgmont)"},{"key":"B28","article-title":"An introduction to the performance of immunohistochemistry","volume-title":"Methods in Molecular Biology","author":"Magaki","year":"2019"},{"key":"B29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13287-022-02858-4","article-title":"Mesenchymal stem cell homing to improve therapeutic efficacy in liver disease","volume":"13","author":"Yuan","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2019.05.004","article-title":"Mesenchymal stromal cell homing: mechanisms and strategies for improvement","volume":"15","author":"Ullah","year":"2019","journal-title":"iScience"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.3390\/ijms24043559","article-title":"Mesenchymal stromal cell-based targeted therapy pancreatic cancer: progress and challenges","volume":"24","author":"Ma","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-021-10320-w","article-title":"Comparative analysis of the therapeutic effects of amniotic membrane and umbilical cord derived mesenchymal stem cells for the treatment of type 2 diabetes","volume":"18","author":"Wang","year":"2022","journal-title":"Stem Cell Rev Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.3390\/jcm9093001","article-title":"Plasma C-Peptide and risk of developing type 2 diabetes in the general population","volume":"9","author":"Sokooti","year":"2020","journal-title":"J Clin Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13287-017-0668-1","article-title":"Human umbilical cord-derived mesenchymal stem cells ameliorate insulin resistance by suppressing NLRP3 inflammasome-mediated inflammation in type 2 diabetes rats","volume":"8","author":"Sun","year":"2017","journal-title":"Stem Cell Res Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e11329","DOI":"10.1016\/j.heliyon.2022.e11329","article-title":"Inter-relationship of Pro- and Anti- inflammatory Biomarkers with the development of Type 2 Diabetes Mellitus","volume":"8","author":"Bashir","year":"2022","journal-title":"Heliyon"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2016.06.028","article-title":"Adiponectin, TNF-\u03b1 and inflammatory cytokines and risk of type 2 diabetes: A systematic review and meta-analysis","volume":"86","author":"Liu","year":"2016","journal-title":"Cytokine"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01076","article-title":"Immunosuppressive property of MSCs mediated by cell surface receptors","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13098-017-0233-1","article-title":"Mesenchymal stem cell therapy in type 2 diabetes mellitus","volume":"9","author":"Zang","year":"2017","journal-title":"Diabetol Metab Syndrome"},{"key":"B40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13287-022-02777-4","article-title":"Mesenchymal stem cells and natural killer cells interaction mechanisms and potential clinical applications","volume":"13","author":"Abbasi","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13098-016-0159-z","article-title":"Interactions between kidney disease and diabetes: dangerous liaisons","volume":"8","author":"Pecoits-Filho","year":"2016","journal-title":"Diabetol Metab Syndrome"},{"key":"B42","article-title":"Relationship between hbA1c and lipid profile seen in Bangladeshi type 2 diabetes mellitus patients attending BIRDEM hospital: A cross-sectional study","volume":"28","author":"Begum","year":"2019","journal-title":"Mymensingh Med J: MMJ"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/stem.3357","article-title":"Mesenchymal stromal cell-mediated immune regulation: A promising remedy in the therapy of type 2 diabetes mellitus","volume":"39","author":"Chen","year":"2021","journal-title":"Stem Cells"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.12.003","article-title":"The role of glucagon in the pathophysiology and treatment of type 2 diabetes","volume":"93","author":"H\u00e6dersdal","year":"2018","journal-title":"Mayo Clinic Proc"},{"key":"B45","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.molmet.2018.01.011","article-title":"Genome-wide analysis of PDX1 target genes in human pancreatic progenitors","volume":"9","author":"Wang","year":"2018","journal-title":"Mol Metab"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1038\/s41598-017-03747-0","article-title":"Selective serotonin reuptake inhibitor, fluoxetine, impairs E-cadherin-mediated cell adhesion and alters calcium homeostasis in pancreatic beta cells","volume":"7","author":"Chang","year":"2017","journal-title":"Sci Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S291932","article-title":"Epigenetic regulation of PDX-1 in type 2 diabetes mellitus","volume":"14","author":"Liu","year":"2021","journal-title":"Diabetes Metab Syndrome Obesity: Targets Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1091757","article-title":"PDX1 is the cornerstone of pancreatic beta-cell functions and identity","volume":"9","author":"Ebrahim","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1677\/JOE-06-0169","article-title":"Differential expression of E-cadherin at the surface of rat \u03b2-cells as a marker of functional heterogeneity","volume":"194","author":"Bosco","year":"2007","journal-title":"J Endocrinol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.2337\/figshare.16826671","article-title":"Glucagon clearance is preserved in type 2 diabetes","volume":"71","author":"Grondahl","year":"2021","journal-title":"Diabetes"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvy022","article-title":"Smooth muscle cell fate and plasticity in atherosclerosis","volume":"114","author":"Allahverdian","year":"2018","journal-title":"Cardiovasc Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1530\/JME-21-0032","article-title":"Collagen type I enhances cell growth and insulin biosynthesis in rat pancreatic cells","volume":"67","author":"Zhu","year":"2021","journal-title":"J Mol Endocrinol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2013.42","article-title":"Inhibition of collagen I accumulation reduces glomerulosclerosis by a Hic-5-dependent mechanism in experimental diabetic nephropathy","volume":"93","author":"Hornigold","year":"2013","journal-title":"Lab Invest"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1536655\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T01:18:24Z","timestamp":1742519904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1536655\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":53,"alternative-id":["10.3389\/fendo.2025.1536655"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1536655","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"article-number":"1536655"}}